Hydrazine

Hydrazine

SCHEMBL2373463

NN.c1ccc2nc3ncccc3cc2c1

nearest known ligand 0.54

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.54
MAPT P10636 3/20 0.54
GLA P06280 2/20 0.54
HPGD P15428 2/20 0.54
ACHE P22303 1/20 0.54
KDM4E B2RXH2 2/20 0.46
HTR3A P46098 1/20 0.46
TP53 P04637 1/20 0.46
HSP90AA1 P07900 1/20 0.46
HSP90AB1 P08238 1/20 0.46
TSHR P16473 1/20 0.46
CASP1 P29466 1/20 0.46
HTT P42858 1/20 0.46
ATM Q13315 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
HSD17B10 Q99714 1/20 0.46
POLB P06746 3/20 0.44
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
KMT2A Q03164 3/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL162529 0.96 ALDH1A1 (0.58) ALDH1A1MAPTGLAHPGDACHE
SCHEMBL8170243 0.88 ALDH1A1 (0.54) ALDH1A1MAPTGLAHPGDACHE
Quinoline SCHEMBL7993280 0.87 ALDH1A1 (0.61) ALDH1A1MAPTGLAHPGDACHE
SCHEMBL13156531 0.82 ALDH1A1 (0.46) ALDH1A1MAPTGLAHPGDACHE
SCHEMBL20272946 0.81 ALDH1A1 (0.44) ALDH1A1MAPTKDM4ETP53HSP90AA1
SCHEMBL832575 0.80 ALDH1A1 (0.48) ALDH1A1MAPTKDM4ETP53HSP90AA1
SCHEMBL29384237 0.80 ALDH1A1 (0.48) ALDH1A1MAPTKDM4ETP53HSP90AA1
SCHEMBL13156534 0.80 NPC1 (0.48) ALDH1A1MAPTGLAHPGDACHE
SCHEMBL997757 0.79 ALDH1A1 (0.54) ALDH1A1MAPTKDM4ETP53HSP90AA1
SCHEMBL13156503 0.77 ALDH1A1 (0.52) ALDH1A1MAPTGLAHPGDACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9029387-B2 Benzonaphthyridinamines as autotaxin inhibitors MERCK PATENT GMBH (DE) 2015-05-12 US disclosed
EP-2552914-A1 BENZONAPHTHYRIDINAMINES AS AUTOTAXIN INHIBITORS Merck Patent GmbH (DE) 2013-02-06 EP disclosed
US-20130012505-A1 BENZONAPHTHYRIDINAMINES AS AUTOTAXIN INHIBITORS MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-01-10 US disclosed
WO-2011116867-A1 BENZONAPHTHYRIDINAMINES AS AUTOTAXIN INHIBITORS MERCK PATENT GMBH (DE) 2011-09-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012505-A1 BENZONAPHTHYRIDINAMINES AS AUTOTAXIN INHIBITORS ENPP2, LYPLAL1, LYPLA1 ALDH1A1 3057/4885MAPT 3567/4885GLA 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.